WALTHAM, Mass., Dec. 9, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM:OXGN - News) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that during a special meeting of stockholders held on December 9, 2008, stockholders approved the proposal to issue additional shares of the Company’s common stock to Symphony ViDA Holdings LLC, related to the previously announced formation of Symphony ViDA, Inc. Symphony ViDA was established by OXiGENE and Symphony to develop OXi4503, OXiGENE’s dual-mechanism, second-generation vascular disrupting agent (VDA), and topical-route ZYBRESTAT for ophthalmology.
